Chronic myeloid leukemia (CML) has become a model in research and management among
malignant disorders. Since the discovery of the presence of a unique and constant …

The prognosis of patients with chronic myelogenous leukemia (CML) has significantly
improved over the last 20 years. Whereas the median survival durations were 4-5 years in …

Leukemias have traditionally served as model systems for research on neoplasia because
of the easy availability of cell material from blood and marrow for diagnosis, monitoring and …

Chronic myeloid leukaemia (CML) was the first neoplastic disease for which knowledge of
the genotype led to a rationally designed therapy. As a result of its well known …

Chronic myeloid leukemia (CML) was the first human malignancy to be associated with a
specific genetic lesion, the Philadelphia chromosome, harboring the BCR-ABL oncogene …

Patients with splenomegaly and abnormally high leukocyte counts were first recognized in
France, Germany, and Scotland in the 1840s. The only well-documented therapy in the 19th …

Chronic myeloid leukemia (CML) has been a model disease in the development of targeted
therapies. After nearly 40 years of the recognition of the chromosomal abnormality that …

The scientists of today have become accustomed to the extremely rapid pace of progress in
the biomedical sciences spurred on by the discovery of recombinant DNA and the advent of …

Background The cause of chronic myeloid leukemia (CML) is a constitutively active BCR-
ABL tyrosine kinase. Imatinib inhibits this kinase, and in a short-term study was superior to …

Purpose: Review the state-of-art knowledge of the biology and therapy of chronic
myelogenous leukemia (CML). Experimental Design: A review of the literature was …